Trial Profile
Development of Immunosuppression Regimens to Facilitate Single Donor Islet Transplantation Using Abatacept.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Islet cell transplant rejection
- Focus Therapeutic Use
- 04 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2012 Planned end date changed from 1 Dec 2010 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 28 Jul 2009 Genentech removed as trial sponsor as reported by ClinicalTrials.gov.